TABLE 1.
Tobramycin profile | Cmax (mg/liter) | AUC0–48.5 h (mg · h/liter) | Bacterial counts (log10 CFU/ml) atb:
|
|||||
---|---|---|---|---|---|---|---|---|
0 h | 0.5 h | 2.5 h | 10.5 h | 24.5 h | 48.5 h | |||
Postdistribution peak (mg/liter) of complete bolus | ||||||||
0 (control) | 0 | 0 | 5.86 ± 0.53 | 5.00 ± 0.24 | 5.71 ± 0.44 | 7.83 ± 0.60 | 8.78 ± 0.52 | 9.16 ± 0.37 |
8 | 27.84 ± 0.74 | 35.90 ± 1.69 | 6.01 ± 0.19 | 2.22 ± 1.28* | 0.22 ± 0.53* | 0.22 ± 0.53* | 3.61 ± 1.00* | 8.40 ± 0.78 |
10 | 35.53 ± 5.06 | 42.29 ± 3.96 | 6.01 ± 0.16 | 0.73 ± 0.33† | NGD*c | NGD* | NGD† | NGD† |
Postdistribution peak of 8 mg/liter to 8.5 h and then reconstituted to (mg/liter): | ||||||||
Control (no antibiotic) | 0 | 0 | 5.89 ± 0.02 | 5.29 ± 0.11 | 5.64 ± 0.36 | 8.02 ± 0.02 | 9.08 ± 0.03 | 9.13 ± 0.02 |
0 | 27.31 ± 0.42 | 30.07 ± 0.32 | 5.89 ± 0.04 | 0.92 ± 0.72* | NGD* | NGD* | 6.99 ± 0.75 | 8.93 ± 0.04 |
0.2 | 26.42 ± 1.5 | 32.92 ± 0.38 | 5.88 ± 0.03 | 0.92 ± 0.72* | NGD* | NGD* | 6.97 ± 0.06 | 8.93 ± 0.03 |
0.4 | 26.99 ± 1.31 | 35.91 ± 0.94 | 5.89 ± 0.03 | 0.92 ± 0.72* | NGD* | NGD* | 6.14 ± 0.54* | 8.93 ± 0.05 |
0.6 | 27.66 ± 0.60 | 38.87 ± 0.67 | 5.89 ± 0.03 | 0.70 ± 0.77* | NGD* | NGD* | 3.88 ± 3.06‡ | 5.97 ± 4.62 |
0.8 | 27.39 ± 1.11 | 41.51 ± 0.56 | 5.89 ± 0.03 | 0.65 ± 0.71* | NGD* | NGD* | NGD‡ | NGD‡ |
1.0 | 27.46 ± 1.13 | 44.66 ± 0.54 | 5.90 ± 0.02 | 0.70 ± 0.77* | NGD* | NGD* | NGD‡ | NGD‡ |
For all groups, values are means ± standard deviations (n = 6).
*, significantly different from control (P < 0.001); †, significantly different from all other exposures (P < 0.001). ‡, Significantly different from other exposures, including control (P < 0.001).
NGD, no growth defect.